409 filings
Page 4 of 21
8-K
fx4 w0mdl0kx5b0u
18 May 22
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints
7:37am
8-K
qi7 2jx7j
25 Mar 22
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
7:36am
8-K
usx bhspu5
14 Feb 22
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
7:10am
8-K
dherel0c6ndvmdzab0n4
2 Dec 21
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
7:17am
8-K
6gzshyq1h3ez5
15 Nov 21
Acasti Pharma Announces Annual Stock Option Grants
12:00am
424B5
etjjjvuv3rxrw695a
10 Nov 21
Prospectus supplement for primary offering
7:23am
8-K
mxq8d3f9v8tw2am0 uwc
10 Nov 21
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022
7:09am
8-K/A
4nmuf
5 Nov 21
Financial Statements and Exhibits
4:07pm
8-K
4rcjgfn
22 Sep 21
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
8:30am
8-K
ymowhs9j
9 Sep 21
Amendments to Articles of Incorporation or Bylaws
4:19pm
8-K
qyypa6d9461nn1xt6j
27 Aug 21
Completion of Acquisition or Disposition of Assets
8:47am
425
g3lndc7 yg69m7umwaf
12 Aug 21
Business combination disclosure
11:00am
8-K
yur63w j6ekw
12 Aug 21
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
10:57am
425
jfo9y 312xb
4 Aug 21
Business combination disclosure
5:03pm
425
gukfd4msuw9birvvcj
4 Aug 21
Business combination disclosure
5:00pm
8-K
8ed avl0xniwgt
23 Jul 21
Other Events
8:43am